# R1 Clinical-Safety Review — mesothelioma (management narrative)

VERDICT: APPROVE

Confidence: 90

Adversarial verdict file (.verdict.md): NOT PRESENT at the sidecar path — no
prior flags to reconcile. Review performed independently.

goldens changed: no (intended: n/a — draft KB narrative, no engine/golden path touched)

## 1. SAFETY — pass
- No unsafe absolute claims. High-stakes statements are correctly hedged
  ("generally not achievable", "highly selected subgroup", "reserved for
  specialized centers").
- The two directive-style statements are safety-protective, not risk-adding:
  single-agent CTLA-4 blockade "should not be used as monotherapy" (grounded
  in the negative tremelimumab data) and referral of curative-intent surgical
  candidates to high-volume centers. Both reduce harm.
- MARS "EPP worse outcomes" is presented with the correct caveats (small
  sample, high perioperative mortality, only randomized evidence) rather than
  as settled fact.

## 2. GROUNDING — pass (DeVita/NCCN standard of care)
- Frontline dual IO (PD-1 + CTLA-4) with largest benefit in non-epithelioid
  histology: consistent with CheckMate 743 / NCCN.
- Antifolate-platinum doublet as established standard, carboplatin substitution,
  single-agent antifolate for platinum-ineligible: standard.
- Anti-VEGF add-on OS benefit without formal regulatory approval (MAPS):
  correctly characterized.
- Maintenance antifolate negative / early-closed trial: accurate.
- Salvage sequencing by prior exposure, ramucirumab+gemcitabine OS signal
  (RAMES) flagged as needing confirmation: accurate.
- ALK-fusion / BAP1-PARP: correctly labeled rare/investigational.
- No fabricated or deprecated regimen detected.
- Source-attribution discipline is good: TTFields device caveat, monitoring/
  surveillance, and imaging-response are each explicitly labeled "general
  oncology standard, not from DeVita's section on this disease" — so nothing
  outside DeVita is mis-cited to DeVita.

## 3. DOSE-FREE — pass
No numeric dose leaked. All numerals are disease stages (I–III, I/II, III/IV)
or trial names (MARS, MARS 2). No mg, mg/m2, AUC, or numbered schedules.

## 4. SCOPE — pass
Framed as decision-support: emphasizes controversy, multidisciplinary
discussion, individualized choice, and referral. "Should be offered/considered/
referred" reads as hedged guidance, not a definitive directive.

## 5. ADVERSARIAL FLAGS — none to reconcile (no .verdict.md).

## Advisory (non-blocking)
- Line 79: doubled trailing parentheticals for TTFields ("...coverage varies)
  (general oncology standard...)") reads slightly awkward; consider merging.
- Consider naming histology-driven frontline choice as the single most
  decision-relevant takeaway near the top of the systemic section for
  clinician scan-ability.

Sources verified against: DeVita, Hellman & Rosenberg 12th ed.; NCCN standard
of care for malignant pleural mesothelioma.
